Abstract
Bestatin, a substance produced by Streptomyces olivoreticuli, inhibits certain cell-membrane-associated enzymes and has been shown to augment immune responses in experimental animals. We have determined whether bestatin medication changed the peripheral lymphocyte population in 15 advanced cancer patients. After 2 weeks of daily, 30 mg oral bestatin medication, the lymphocyte counts remained essentially unchanged, but the frequency of E-rosette-forming lymphocytes increased. In vitro stimulation of the lymphocytes with PHA or PPD remained essentially unchanged while the natural-killer activity of the lymphocyte population increased in most patients. Bestatin treatment caused no detectable side effects.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aoyagi T, Suda H, Nagai M, Ogawa K, Suzuki J, Takeuchi T, Umezawa H (1976) Aminopeptidase activities on the surface of mammalian cells. Biochem Biophys Acta 452:131–143
Blomgren H (1975) Role of B-cells in the expression of the PPD response of human lymphocytes in vitro. Scand J Immunol 4:499–510
Blomgren H, Glas U, Meén B, Wasserman J (1974) Blood lymphocytes after radiation therapy of mammary carcinoma. Acta Radiol Ther Phys Biol 13:185–200
Einhorn S, Blomgren H, Strander H (1978) Interferon and spontaneous cytotoxicity in man. I. Enhancement of spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int J Cancer 22:405–412
Jondal M, Holm G, Wigzell H (1972) Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med 136:207–215
Kasai M, Leclerc JC, McVay-Boudreau L, Shen FW, Cantor H (1979) Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo. J Exp Med 149:1260–1264
Kiessling R, Petrányi G, Klein G, Wigzell H (1975) Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semisyngeneic mice against a mouse lymphoma line. Int J Cancer 15:933
Lilliehöök B, Blomgren H (1974) Strong stimulation of CBA lymphocytes in the mixed lymphocyte interaction with cells from the H-2 identical strain C3H. Scand J Immunol 3:627–635
Suda H, Takita T, Aoyagi T, Umezawa H (1976) The structure of bestatin. J Antibiot (Tokyo) 29:100–101
Trinchieri G, Santoli D (1978) Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1333
Umezawa H (1977) Recent advances in bioactive microbial secondary metabolites. J Antibiot (Tokyo) 30:138–163
Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T (1976) Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J Antibiot (Tokyo) 29:97–99
Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T (1976) Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo) 29:857–859
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Blomgren, H., Strender, L.E., Edsmyr, F. (1980). Bestatin Treatment and the Peripheral Lymphocyte Population in Cancer Patients. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 75. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81491-4_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-81491-4_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81493-8
Online ISBN: 978-3-642-81491-4
eBook Packages: Springer Book Archive